Nantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director.
Pauporté will lead the clinical development of the firm’s lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug’s potential in other cancer indications.
She brings over 20 years of biomedical and clinical research experience to the team, and joins from the French National Cancer Institute (INCa) where she supervised the insitute’s breast cancer research programme.
Prior to this, Pauporté worked for the UNICANCER hospital group as a project leader overseeing both clinical research and regulatory affairs. She also brings experience as a research coordinator at Takeda Laboratories, where she served between 1997 and 2004.
Alain Chatelin, medical director at OSE Immunotherapeutics, said: “We are very pleased to have Iris join our team.
“She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology.”